|
Age at diagnosis, years, Median (IQR)
|
63.00 (59.00–67.00)
|
63.00 (60.00–67.00)
|
62.50 (55.50–67.00)
|
0.362
|
|
Sex
|
|
Male
|
107 (92.2%)
|
59 (51.3%)
|
48 (41.7%)
| |
|
Female
|
8 (7.0%)
|
4 (3.5%)
|
4 (3.5%)
|
0.778
|
|
ECOG performance status
|
|
0–1
|
84 (73.0%)
|
44 (38.3%)
|
40 (34.8%)
| |
|
2
|
31 (27.0%)
|
19 (16.5%)
|
12 (10.4%)
|
0.394
|
|
Smoking pack-years
| |
|
≥ 10
|
80
|
45
|
35
| |
|
0–10
|
4
|
3
|
1
| |
|
0
|
24
|
12
|
12
| |
|
Unkown
|
7
|
3
|
4
|
0.717
|
|
Histology
|
|
Squamous carcinoma
|
78 (67.8%)
|
49 (42.2%)
|
35 (30.4%)
| |
|
Adenocarcinoma
|
34 (29.6%)
|
19 (16.5%)
|
15 (13.0%)
| |
|
Others
|
3 (2.6%)
|
1 (0.9%)
|
2 (1.7%)
|
0.683
|
|
cT stage (AJCC 8th ed)
|
|
T1
|
14 (12.2%)
|
8 (7.0%)
|
6 (5.2%)
| |
|
T2
|
31 (26.7%)
|
20 (17.2%)
|
11 (9.57%)
| |
|
T3
|
27 (23.5%)
|
12 (10.4%)
|
15 (13.0%)
| |
|
T4
|
43 (37.4%)
|
23 (20.0%)
|
20 (17.4%)
|
0.492
|
|
cN stage
|
|
N1
|
6 (5.2%)
|
2 (1.7%)
|
4 (3.5%)
| |
|
N2
|
73 (63.5%)
|
39 (33.9%)
|
34 (29.6%)
| |
|
N3
|
36 (31.3%)
|
22 (19.1%)
|
14 (12.2%)
|
0.417
|
|
Stage
|
|
IIIA
|
33 (28.7%)
|
18 (15.7%)
|
15 (13.0%)
| |
|
IIIB
|
61 (53.0%)
|
33 (28.7%)
|
28 (24.3%)
| |
|
IIIC
|
21 (18.3%)
|
12 (10.4%)
|
9 (7.8%)
|
0.971
|
|
TLCs, cells/μL (median, IQR)
|
|
Baseline
|
1600 (1400–2000)
|
1600 (1300–1900)
|
1800 (1400–2200)
|
0.037
|
|
Pre-RT
|
1800 (1400–2100)
|
1600 (1280–1900)
|
1965 (1700–2252)
|
< 0.001
|
|
TLC nadir during the course of RT
|
500 (380–700)
|
390 (300–470)
|
700 (600–830)
|
< 0.001
|
|
1 month after RT
|
915 (700–1100)
|
800 (598–1100)
|
995 (882–1232)
|
0.004
|
|
2 month after RT
|
900 (700–1100)
|
740 (600–982)
|
1000 (810–1195)
|
< 0.001
|
|
Tumor volume, cm3 (median, IQR)
| |
|
GTV
|
56.85 (32.47–129.35)
|
87.69 (45.58–144.92)
|
43.40 (21.84–95.52)
|
0.006
|
|
PTV
|
146.03 (74.20–247.39)
|
160.95 (80.69–258.92)
|
124.82 (71.13–224.05)
|
0.192
|
|
EQD2 (Gy or Gy[RBE]) (median, IQR)
|
64.00 (60.00–65.00)
|
62.87 (60.00–65.10)
|
65.00 (60.00–65.00)
|
0.755
|
|
BED (Gy)
|
76.80 (72.00–78.00)
|
75.44 (72.00–78.13)
|
78 (72–78)
|
0.768
|
|
Fractions, number (median, IQR)
|
25 (20–30)
|
25 (25–30)
|
25 (20–30)
|
0.141
|
|
OTT, days (median, IQR)
|
39 (31–43)
|
39 (33–43)
|
35 (29–43)
|
0.281
|
|
Key mean normal tissue doses, cGy (median, IQR)
|
|
Mean lung dose
|
1275 (1078–1454)
|
1354.90 (1146.00–1480.00)
|
1165 (990–1386)
|
0.007
|
|
Mean heart dose
|
601 (420–1261.50)
|
886 (439.00–1502.25)
|
518 (384–936.90)
|
0.041
|
|
Radiation technique
|
|
3D conformal
|
28 (24.3%)
|
16 (13.9%)
|
12 (10.4%)
| |
|
Intensity modulated
|
37 (32.2%)
|
19 (16.5%)
|
18 (15.7%)
| |
|
Helical Tomotherapy
|
50 (43.5%)
|
28 (24.3%)
|
22 (19.1%)
|
0.874
|
|
Concurrent chemoradiation (sequential)
|
|
Yes
|
31 (27.0%)
|
15 (12.9%)
|
16 (13.9%)
| |
|
No
|
84 (73.0%)
|
48 (41.7%)
|
36 (31.3%)
|
0.403
|
|
Induction chemotherapy
|
|
Yes
|
91 (79.1%)
|
54 (47.0%)
|
37 (32.2%)
| |
|
No
|
24 (20.9%)
|
9 (7.8%)
|
15 (13.0%)
|
0.056
|
|
Adjuvant chemotherapy
|
|
Yes
|
61 (53.0%)
|
31 (27.0%)
|
30 (26.1%)
| |
|
No
|
54 (47.0%)
|
32 (27.8%)
|
22 (19.1%)
|
0.364
|
